These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 32815913

  • 1. Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?
    Seidi Zadeh O, Ahmadinejad M, Amoohossein B, Homayoun S.
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):382-386. PubMed ID: 32815913
    [Abstract] [Full Text] [Related]

  • 2. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
    Favaloro EJ, Mohammed S, Vong R, Pasalic L.
    Methods Mol Biol; 2023 Sep; 2663():679-691. PubMed ID: 37204745
    [Abstract] [Full Text] [Related]

  • 3. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
    Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J.
    Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
    [Abstract] [Full Text] [Related]

  • 4. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH, Kelley L, Green D.
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
    Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH, Hemophilia Inhibitor Research Study Investigators.
    J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
    [Abstract] [Full Text] [Related]

  • 6. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
    Qin HH, Xing ZF, Wang XF, Ding QL, Xi XD, Wang HL.
    Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
    [Abstract] [Full Text] [Related]

  • 7. Von Willebrand disease type 2N: An update.
    Seidizadeh O, Peyvandi F, Mannucci PM.
    J Thromb Haemost; 2021 Apr; 19(4):909-916. PubMed ID: 33497541
    [Abstract] [Full Text] [Related]

  • 8. Type 2N von Willebrand disease: Characterization and diagnostic difficulties.
    Casonato A, Galletta E, Sarolo L, Daidone V.
    Haemophilia; 2018 Jan; 24(1):134-140. PubMed ID: 29115006
    [Abstract] [Full Text] [Related]

  • 9. Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype.
    van Meegeren ME, Mancini TL, Schoormans SC, van Haren BJ, van Duren C, Diekstra A, Laros-van Gorkom BA, Brons PP, Simons A, Hoefsloot L, van Heerde WL.
    Haemophilia; 2015 Sep; 21(5):e375-83. PubMed ID: 26207643
    [Abstract] [Full Text] [Related]

  • 10. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1.
    Schneppenheim R, Budde U, Krey S, Drewke E, Bergmann F, Lechler E, Oldenburg J, Schwaab R.
    Thromb Haemost; 1996 Oct; 76(4):598-602. PubMed ID: 8903002
    [Abstract] [Full Text] [Related]

  • 11. The Lesson Learned from the New c.2547-1G > T Mutation Combined with p.R854Q: When a Type 2N Mutation Reveals a Quantitative von Willebrand Factor Defect.
    Casonato A, Cozzi MR, Ferrari S, Rubin B, Gianesello L, De Marco L, Daidone V.
    Thromb Haemost; 2022 Sep; 122(9):1479-1485. PubMed ID: 35189660
    [Abstract] [Full Text] [Related]

  • 12. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D.
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [Abstract] [Full Text] [Related]

  • 13. Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project.
    Pérez-Rodríguez A, Batlle J, Pinto JC, Corrales I, Borràs N, Garcia-Martínez I, Cid AR, Bonanad S, Parra R, Mingot-Castellano ME, Navarro N, Altisent C, Pérez-Montes R, Moretó A, Herrero S, Soto I, Mosteirín NF, Jiménez-Yuste V, Jacob AA, Fontanes E, Mateo J, Quismondo NC, Batlle F, Vidal F, López-Fernández MF, investigators and centers involved in the PCM-EVW-ES projectComplexo Hospitalario Universitario A Coruña, INIBIC, A Coruña, Spain..
    Haemophilia; 2021 Nov; 27(6):1007-1021. PubMed ID: 34494337
    [Abstract] [Full Text] [Related]

  • 14. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
    Ryu JH, Bauer KA, Schulman S.
    J Thromb Haemost; 2023 Dec; 21(12):3508-3510. PubMed ID: 37734716
    [Abstract] [Full Text] [Related]

  • 15. Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.
    Lapić I, Radić Antolic M, Boban A, Coen Herak D, Rogić D, Zadro R.
    Croat Med J; 2022 Apr 30; 63(2):166-175. PubMed ID: 35505650
    [Abstract] [Full Text] [Related]

  • 16. Identifying carriers of type 2N von Willebrand disease: procedures and significance.
    Casonato A, Pontara E, Sartorello F, Cattini MG, Perutelli P, Bertomoro A, Gallinaro L, Pagnan A.
    Clin Appl Thromb Hemost; 2007 Apr 30; 13(2):194-200. PubMed ID: 17456630
    [Abstract] [Full Text] [Related]

  • 17. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov 30; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 18.
    Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Johnsen J.
    ; 1993 Nov 30. PubMed ID: 20301765
    [Abstract] [Full Text] [Related]

  • 19. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
    Doruelo AL, Haberichter SL, Christopherson PA, Boggio LN, Gupta S, Lentz SR, Shapiro AD, Montgomery RR, Flood VH.
    J Thromb Haemost; 2017 Aug 30; 15(8):1559-1566. PubMed ID: 28544236
    [Abstract] [Full Text] [Related]

  • 20. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 Aug 30; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.